{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-004548","form_type":"8-K","ticker":"CTSO","cik":"0001175151","company_name":"Cytosorbents Corp","filed_at":"2024-01-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.566492+00:00","generated_at":"2026-06-06T22:27:32.885608+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Positive RCT results for CytoSorb in heart transplant show reduced organ failure and shorter ICU stays","bullets":["Vasoplegic syndrome rate 20% vs 48% control (p=0.028); odds 6.4× lower in CytoSorb group.","Acute kidney injury 36.7% vs 76.0% control (p=0.004); no renal replacement therapy needed (0% vs 16%).","Median ICU stay 8.5 days vs 12 days control (p=0.022); mechanical ventilation 25 vs 65 hours.","No removal of anti-rejection drug mycophenolic acid and no device-related adverse events reported.","Study published in European Society of Cardiology journal ESC Heart Failure."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-004548","json":"https://secwatch.observer/filing/0001104659-24-004548.json","markdown":"https://secwatch.observer/filing/0001104659-24-004548.md","text":"https://secwatch.observer/filing/0001104659-24-004548.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924004548/0001104659-24-004548-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1175151/000110465924004548/tm243541-1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T22:27:32.885608+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}